Axsome Therapeutics (AXSM) Enterprise Value (2015 - 2026)
Axsome Therapeutics recorded quarterly Enterprise Value of -$305.1 million in Q1 2026, up 5.52% quarter-over-quarter from -$322.9 million in Q4 2025, and down 1.4% year-over-year from -$309.4 million in Q1 2025.
Axsome Therapeutics' Enterprise Value history runs 12 years deep, the most recent figure standing at -$305.1 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 1.4% year-over-year to -$305.1 million; the TTM figure through Mar 2026 stood at -$305.1 million (down 1.4% YoY), while the FY2025 annual figure was -$322.9 million, down 2.4% from the prior year.
- Enterprise Value came in at -$305.1 million for Q1 2026 at Axsome Therapeutics, up from -$322.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$73.4 million in Q2 2022 to a low of -$437.1 million in Q2 2023.
- A 5-year average of -$289.4 million and a median of -$315.4 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 48.56% in 2022 and tumbled 495.57% in 2023, its largest moves.
- Axsome Therapeutics' Enterprise Value stood at -$200.8 million in 2022, then plunged by 92.29% to -$386.2 million in 2023, then rose by 18.34% to -$315.4 million in 2024, then declined by 2.4% to -$322.9 million in 2025, then increased by 5.52% to -$305.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$305.1 million, -$322.9 million, and -$325.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -305.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -305.10 Mn |
| Dec 31, 2025 | -322.93 Mn |
| Sep 30, 2025 | -325.30 Mn |
| Jun 30, 2025 | -303.02 Mn |
| Mar 31, 2025 | -300.90 Mn |
| Dec 31, 2024 | -315.35 Mn |
| Sep 30, 2024 | -327.30 Mn |
| Jun 30, 2024 | -315.66 Mn |
| Mar 31, 2024 | -331.44 Mn |
| Dec 31, 2023 | -386.19 Mn |
| Sep 30, 2023 | -416.60 Mn |
| Jun 30, 2023 | -437.11 Mn |
| Mar 31, 2023 | -246.50 Mn |
| Dec 31, 2022 | -200.84 Mn |
| Sep 30, 2022 | -227.52 Mn |
| Jun 30, 2022 | -73.39 Mn |
| Mar 31, 2022 | -84.70 Mn |
| Dec 31, 2021 | -86.47 Mn |
| Sep 30, 2021 | -114.60 Mn |
| Jun 30, 2021 | -141.22 Mn |
| Mar 31, 2021 | -164.66 Mn |
| Dec 31, 2020 | -183.88 Mn |
| Sep 30, 2020 | -202.36 Mn |
| Jun 30, 2020 | -190.68 Mn |
| Mar 31, 2020 | -197.31 Mn |
| Dec 31, 2019 | -219.97 Mn |
| Sep 30, 2019 | -43.64 Mn |
| Jun 30, 2019 | -53.75 Mn |
| Mar 31, 2019 | -42.62 Mn |
| Dec 31, 2018 | -13.97 Mn |
| Sep 30, 2018 | -15.22 Mn |
| Jun 30, 2018 | -20.35 Mn |
| Mar 31, 2018 | -26.63 Mn |
| Dec 31, 2017 | -34.02 Mn |
| Sep 30, 2017 | -31.67 Mn |
| Jun 30, 2017 | -37.99 Mn |
| Mar 31, 2017 | -45.02 Mn |
| Dec 31, 2016 | -36.62 Mn |
| Sep 30, 2016 | -33.89 Mn |
| Jun 30, 2016 | -38.75 Mn |
| Mar 31, 2016 | -44.08 Mn |
| Dec 31, 2015 | -48.04 Mn |
| Sep 30, 2015 | -4.62 Mn |
| Jun 30, 2015 | -6.41 Mn |
| Mar 31, 2015 | -1.69 Mn |